Ibrutinib Plus Obinutuzumab Elicits Intriguing... - CLL Support
Ibrutinib Plus Obinutuzumab Elicits Intriguing Survival Benefits in Relapsed/Refractory CLL - OncLive interviews Dr C Ryan, Dana Farber
You need to be a member of this community to see this post.
Read more about...
10 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
fixed-duration regimen of obinutuzumab plus venetoclax reduced the risk of disease progression...
AbbVie Pharm--positive phase 3 for CLL!
adverse reactions in patients receiving venetoclax in combination with obinutuzumab were pneumonia,...
Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
dose-escalation trial, the regimen led to a high rate of undetectable minimal residual disease...
Sequential And Combination Treatments With Novel Agents (Oct. 2019)
monotherapies until disease progression or if they should preferably be combined in time-limited...
Potential Early Drivers of Disease in Treatment-Naive CLL Identified
early CLL disease and progression.”
High‐risk prognostic markers such as del(17p), mutated TP53 and...
Related Posts
- An Early Look at When CAR-T Therapy Fails Patients With CLL
- Acalabrutinib exhibits comparable efficacy, superior safety to ibrutinib for CLL (finally!)
- Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
New poster... Tirabrutinib study
Aggressive CLL - Richter's Transformation
